We develop and produce highly specialized targeted investor and business development conferences exclusively for the biopharmaceutical and life sciences industries.
With over 20 years’ experience connecting leaders of innovative biotech companies with key stakeholders, investors and advisors, we create ideal environments to examine and address opportunities and challenges in today’s biotech industry.
Get to know us, a respected leader in biotech investor conferences and highly targeted leadership events.
Who we are ⇢
See how we create communities that foster lasting and mutually beneficial relationships.
What we do ⇢
How innovation is shaping the biopharmaceutical industry.
What we think ⇢
The greatest ideas and innovations are those that fill a large gap in a field. And Biotech Showcase (BTS) was created for just such a purpose. There are hundreds, if not thousands, of biotech companies that are not ready for financing with the bulge bracket players – the largest and most recognized banks – like JPMorgan. Yet, they are ready to present their work and show investors how they have been hitting marks and building profiles. Thus, the creation of BTS. A place where small and mid-sized (and growing into larger) biotech companies can present, meet potential investors and partners, and know that the event organizers are on their side. And more importantly, fill that gap in the biotech space by helping those smaller companies get where they need to be.
The last 20 years have witnessed a seismic change in the biotech industry - and the world. Not only has the rapid growth of science and technological advances changed what is possible in the business of biotechnology, but so too have business models and investment acumen. The entire space has experienced growth and maturity that newer entrants wouldn’t believe.
Those of us who have lived, as well as instigated, the evolution couldn’t be prouder of the biotech industry and the key players who have facilitated the changes that make the future possible. Today it is hard to believe that 20 years ago there was no such thing as transparency between pharma and biotech, and to be honest, it was because pharma was comfortable with their pipelines and didn’t want much to do with the untested and mostly unproven brave new world that was biotechnology.
